DOT1L and cancer: Cancer epigenetics is a rapidly progressing field of oncology that has recently demonstrated the use of epigenetic drugs as targeted treatments in preclinical models of several cancer types, such as EZH2 inhibitors in B-cell lymphomas and rhabdoid tumors and DOT1L inhibitors in acute myeloid leukemia [1-3].